18F-αvβ6-BP for Cancer

Recruiting in Palo Alto (17 mi)

Overseen byJulie Sutcliffe

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Julie L. Sutcliffe, Ph.D

No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Eligibility Criteria

This trial is for people with primary or metastatic breast, colorectal, lung, or pancreatic cancer who can stay still for PET scans and have a good performance status. It's not for those with severe kidney/liver issues, very short life expectancy, pregnant/breastfeeding women, recent investigational drug use, or inability to undergo PET/CT scans.

Inclusion Criteria

I am fully active or have some restrictions but can still care for myself.

I can stay still for up to an hour.

My cancer is in the breast, colorectal, lung, or pancreas.

See 1 more

Exclusion Criteria

Lack of availability for follow-up assessments

I am currently pregnant or breastfeeding.

You are unable to have a PET/CT scan.

See 4 more

Treatment Details

Interventions

18F-αvβ6-BP (Radiotracer)

Trial OverviewThe study tests the safety and imaging effectiveness of a radiotracer called 18F-αvβ6-binding-peptide in detecting cancers such as breast, colorectal, lung and pancreatic when used during PET scans.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: 18F-αvβ6-BPExperimental Treatment1 Intervention

Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.